LIPONEX PROVIDES CLINICAL TRIAL UPDATE.Liponex Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :LPX LPX Louisiana Pacific (stock symbol) LPX Leipzig Power Exchange LPX Low Profile Extended LPX Long-Pulse Experiment LPX Low Profile Extension ), Ottawa, Canada, a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein High density lipoprotein (HDL) A fraction of total serum lipids, the so called "good" cholesterol. Mentioned in: Hypercholesterolemia (HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. ), often called "good cholesterol," has provided an update on its preparations for its Phase I/II clinical trial of its lead compound CRD CRD See Central Registration Depository (CRD). 5, being developed for the treatment of dyslipidemia and heart disease. Liponex has now received the bulk active pharmaceutical ingredient (API) from its contract manufacturer and has successfully completed its quality testing and analysis. The API is currently undergoing compounding with quality testing of final drug product on schedule for completion in August prior to use in the upcoming clinical trial. Additionally, patient screening and enrollment for the trial is nearing completion and the company remains on track to begin dosing later this quarter. "We have worked diligently with our partners to rapidly secure newly formulated clinical material that meets our high standards for quality," said Bill Dickie, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Liponex. "Our clinical strategy is moving ahead as envisioned and we are looking forward to testing CRD5 in dyslipidemic patients for the first time later this quarter." The Phase I/II dose-ranging trial will take place at The Riverside Hospital in Ottawa, and will involve 50 dyslipidemic patients (patients with low HDL and high LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. ). Following dietary lead in, expected to begin in August, patients will be given daily doses of the latest formulation of CRD5 in capsule form. The treatment period for each patient will be 12 weeks. The primary endpoints for the trial are safety and an increase in serum HDL, with triglyceride and LDL reductions as secondary endpoints. About Liponex Liponex is a biopharmaceutical company specializing in developing products related to High Density Lipoprotein (HDL), often called "good cholesterol." Its drug candidates relate to the various roles of HDL as a transport vehicle, including removing excess cholesterol from the body, delivering molecules to cells and removing unwanted materials from the body. Liponex is listed on the TSX under the ticker "LPX". For more information, visit http://www.liponex.ca or call 613/234-7227, ext. 234. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion